Faculty profile

Paul Schaffer

ResearcherChemistryUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Paul Schaffer

Researcher

Chemistry

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
27 publications in the last five years, latest in 2026.
Senior (last) author on 7 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2015.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cancer Bio-Inorganic Chemistry 3603 Imaging Agents Life Sciences 1201 Medical And Health Sciences 1211 Pharmacology 6404 Radiometals Radiopharmaceuticals

Latest papers

Modeling the yields of225Ra/225Ac and the resulting225Ac radioisotopic purity from proton irradiation of232Th at 100-800 MeV.
Physics in medicine and biology · 2026
Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.
ACS bio & med chem Au · 2026
Estimation of absorbed doses in computational mouse and human phantoms receiving229Th-derived free225Ac.
Physics in medicine and biology · 2026

All 83 publications

Latest funding

Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives
CIHR · 2022 · Co-investigator
$596,701
Leveraging Trans-Canada Expertise and Resources to Design and Evaluate Novel Auger Electron-Emitting Radioimmunotherapies (RIT) for Metastatic Triple-Negative Breast Cancer (TNBC)
CIHR · 2021 · Co-investigator
$562,275
High Resolution ESI Mass Spectrometer
NSERC · 2018 · Co-investigator
$150,000

All 9 grants and awards

83 publications.

Modeling the yields of225Ra/225Ac and the resulting225Ac radioisotopic purity from proton irradiation of232Th at 100-800 MeV.

Jang J, Radchenko V, Miao Q, Wada Y, Schaffer P, Hoehr C

Physics in medicine and biology2026

DOI: 10.1088/1361-6560/ae3659 PMID: 41512455

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.

McNeil BL, Wharton L, Chen CC, Merkens H, Čolović M, Rodríguez-Rodríguez C, Wilson J, Mair S, Zhang C, McDonagh AW, Lin KS, Bénard F, Wuest F, Schaffer P, Ramogida CF

ACS bio & med chem Au2026

DOI: 10.1021/acsbiomedchemau.5c00224 PMID: 41726328

Estimation of absorbed doses in computational mouse and human phantoms receiving229Th-derived free225Ac.

Jang J, Tanaka T, Ozeki AN, Imura R, Higaki S, Kobayashi M, Miao Q, Akimitsu N, Kumakura Y, Nakano T, Schaffer P, Wada Y

Physics in medicine and biology2026

DOI: 10.1088/1361-6560/ae3b04 PMID: 41558174

Theoretical optimal232Th target thicknesses for225Ac production at proton energies of 70-200 MeV.

Jang J, Schaffer P, Radchenko V, Moskven L, Akimitsu N, Wada Y, Hoehr C

Physics in medicine and biology2025

DOI: 10.1088/1361-6560/adfcae PMID: 40825360

Evaluating a triaza-18-crown-6 picolinate chelator for [212/203Pb]Pb2+ and [212/213Bi]Bi3+ theranostics.

Fiaccabrino D, Masvikeni T, McNeil BL, Patrick BO, Jaraquemada-Peláez MG, Schaffer P, Orvig C

Dalton transactions (Cambridge, England : 2003)2025

DOI: 10.1039/d5dt01103e PMID: 40698437

In vivoquantitative SPECT imaging of actinium-226: feasibility and proof-of-concept.

Koniar H, Wharton L, Ingham A, Rodríguez-Rodríguez C, Kunz P, Radchenko V, Yang H, Rahmim A, Uribe C, Schaffer P

Physics in medicine and biology2024Senior author

DOI: 10.1088/1361-6560/ad5c37 PMID: 38925140

Misfolded protein deposits in Parkinson's disease and Parkinson's disease-related cognitive impairment, a [11C]PBB3 study.

Matarazzo M, Pérez-Soriano A, Vafai N, Shahinfard E, Cheng KJ, McKenzie J, Neilson N, Miao Q, Schaffer P, Shinotoh H, Kordower JH, Sossi V, Stoessl AJ

NPJ Parkinson's disease2024

DOI: 10.1038/s41531-024-00708-z PMID: 38702305

Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.

Koniar H, Wharton L, Ingham A, Morales Oliver AP, Merkens H, Rodríguez-Rodríguez C, Kunz P, Radchenko V, Yang H, Rahmim A, Uribe C, Schaffer P

Journal of nuclear medicine : official publication, Society of Nuclear Medicine2024Senior author

DOI: 10.2967/jnumed.124.267999 PMID: 39362766

Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-αMSH and [161Tb]Tb-crown-αMSH.

Wharton L, McNeil SW, Zhang C, Engudar G, Van de Voorde M, Zeisler J, Koniar H, Sekar S, Yuan Z, Schaffer P, Radchenko V, Ooms M, Kunz P, Bénard F, Yang H

Nuclear medicine and biology2024

DOI: 10.1016/j.nucmedbio.2024.108925 PMID: 38796924

H3trica: Versatile Macrocyclic Chelator for [225Ac]Ac3+ and [155/161Tb]Tb3+ Theranostics.

Fiaccabrino D, Masvikeni T, Jaraquemada-Peláez MG, Orvig C, Schaffer P

Inorganic chemistry2024Senior author

DOI: 10.1021/acs.inorgchem.4c01180 PMID: 39013439

Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives

Co-investigatorCIHR2022Project Grant

Principal investigators: Yang, Hua; Benard, Francois

Keywords: A-Melanocyte-Stimulating Hormone; Alpha Particle Emitting Radionuclides; Melanocortin 1 Receptor; Melenoma Treatment; Radiochemistry Development; Radiopharmaceutical Development; Targeted Radionuclide Therapy

$596,701

Leveraging Trans-Canada Expertise and Resources to Design and Evaluate Novel Auger Electron-Emitting Radioimmunotherapies (RIT) for Metastatic Triple-Negative Breast Cancer (TNBC)

Co-investigatorCIHR2021Project Grant

Principal investigators: Radchenko, Valery; Reilly, Raymond M

Keywords: Radiopharmaceutical Science

$562,275

High Resolution ESI Mass Spectrometer

Co-investigatorNSERC2018Research Tools and Instruments

Principal investigators: Ryan, Katherine

$150,000

Targeted radiopharmaceuticals to improve cancer diagnosis and treatment

Co-investigatorCIHR2015Foundation Grant

Principal investigators: Benard, Francois

Keywords: Breast Cancer; Molecular Imaging; Nuclear Medicine; Positron Emission Tomography; Prostate Cancer; Radioisotopes; Radionuclide Therapy; Radiopharmaceuticals

$1,432,266

Theranostic Vectors to Treat Cancer with Radiometals

Principal investigatorCIHR2015Collaborative Health Research Projects (NSERC partnered)

Principal investigators: Orvig, Christopher E; Benard, Francois; Schaffer, Paul

Keywords: Bio-Inorganic Chemistry 3603; Cancer; Imaging Agents; Life Sciences 1201; Medical And Health Sciences 1211; Pharmacology 6404; Radiometals; Radiopharmaceuticals; Targetting; Therapeutic Agents

$359,446

ISOSIM - ISOtopes for Science and Medicine

Co-investigatorNSERC2014Collaborative Research and Training Experience

Principal investigators: Kruecken, Reiner

$1,650,000

The xc- (cystine) transporter as a novel imaging biomarker of oxidative stress

Nominated PICIHR2014Operating Grant

Principal investigators: Schaffer, Paul

Keywords: Amino Acid Transporter; Cancer; Molecular Imaging; Oxidative Stress; Positron Emission Tomography; Radiochemistry; Real Time Pcr; Western Blot

$276,581

Radiometals produced by liquid targets for molecular imaging of cancer

Co-investigatorCIHR2011Collaborative Health Research Projects (NSERC partnered)

Principal investigators: Benard, Francois

Keywords: Breast Cancer; Cyclotron; Molecular Imaging; Monoclonal Antibodies; Nuclear Chemistry; Nuclear Medicine; Nuclear Physics; Radiochemistry; Radioisotopes; Tyrosine Kinase Receptors

$420,079

Cyclotron-based production of technetium radioisotopes

Co-investigatorCIHR2009Alternative Radiopharmaceuticals for Medical Imaging

Principal investigators: Benard, Francois; Ruth, Thomas J

Keywords: Cyclotron; Nuclear Medicine; Positron Emission Tomography; Radioisotopes; Technetium-94m; Technetium-99m

$78,800

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Paul Schaffer

Research

Latest papers

Latest funding

Modeling the yields of225Ra/225Ac and the resulting225Ac radioisotopic purity from proton irradiation of232Th at 100-800 MeV.

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.

Estimation of absorbed doses in computational mouse and human phantoms receiving229Th-derived free225Ac.

Theoretical optimal232Th target thicknesses for225Ac production at proton energies of 70-200 MeV.

Evaluating a triaza-18-crown-6 picolinate chelator for [212/203Pb]Pb2+ and [212/213Bi]Bi3+ theranostics.

In vivoquantitative SPECT imaging of actinium-226: feasibility and proof-of-concept.

Misfolded protein deposits in Parkinson's disease and Parkinson's disease-related cognitive impairment, a [11C]PBB3 study.

Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.

Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-αMSH and [161Tb]Tb-crown-αMSH.

H3trica: Versatile Macrocyclic Chelator for [225Ac]Ac3+ and [155/161Tb]Tb3+ Theranostics.

Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives

Leveraging Trans-Canada Expertise and Resources to Design and Evaluate Novel Auger Electron-Emitting Radioimmunotherapies (RIT) for Metastatic Triple-Negative Breast Cancer (TNBC)

High Resolution ESI Mass Spectrometer

Targeted radiopharmaceuticals to improve cancer diagnosis and treatment

Theranostic Vectors to Treat Cancer with Radiometals

ISOSIM - ISOtopes for Science and Medicine

The xc- (cystine) transporter as a novel imaging biomarker of oxidative stress

Radiometals produced by liquid targets for molecular imaging of cancer

Cyclotron-based production of technetium radioisotopes

Frequent collaborators

Valery Radchenko

Kuo-Shyan Lin

Hua Yang

Vesna Sossi

Arman Rahmim

Carlos Uribe

Francois Benard

Frank Wuest

Piotr Kozlowski

John F Valliant

Matthew Farrer

Paul Schaffer

Research

Latest papers

Latest funding

Modeling the yields of225Ra/225Ac and the resulting225Ac radioisotopic purity from proton irradiation of232Th at 100-800&#x2009;MeV.

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.

Estimation of absorbed doses in computational mouse and human phantoms receiving229Th-derived free225Ac.

Theoretical optimal232Th target thicknesses for225Ac production at proton energies of 70-200&#x2009;MeV.

Evaluating a triaza-18-crown-6 picolinate chelator for [212/203Pb]Pb2+ and [212/213Bi]Bi3+ theranostics.

In vivoquantitative SPECT imaging of actinium-226: feasibility and proof-of-concept.

Misfolded protein deposits in Parkinson's disease and Parkinson's disease-related cognitive impairment, a [11C]PBB3 study.

Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.

Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-&#x3b1;MSH and [161Tb]Tb-crown-&#x3b1;MSH.

H3trica: Versatile Macrocyclic Chelator for [225Ac]Ac3+ and [155/161Tb]Tb3+ Theranostics.

Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives

Leveraging Trans-Canada Expertise and Resources to Design and Evaluate Novel Auger Electron-Emitting Radioimmunotherapies (RIT) for Metastatic Triple-Negative Breast Cancer (TNBC)

High Resolution ESI Mass Spectrometer

Targeted radiopharmaceuticals to improve cancer diagnosis and treatment

Theranostic Vectors to Treat Cancer with Radiometals

ISOSIM - ISOtopes for Science and Medicine

The xc- (cystine) transporter as a novel imaging biomarker of oxidative stress

Radiometals produced by liquid targets for molecular imaging of cancer

Cyclotron-based production of technetium radioisotopes

Frequent collaborators

Valery Radchenko

Kuo-Shyan Lin

Hua Yang

Vesna Sossi

Arman Rahmim

Carlos Uribe

Francois Benard

Frank Wuest

Piotr Kozlowski

John F Valliant

Matthew Farrer

Modeling the yields of225Ra/225Ac and the resulting225Ac radioisotopic purity from proton irradiation of232Th at 100-800 MeV.

Theoretical optimal232Th target thicknesses for225Ac production at proton energies of 70-200 MeV.

Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-αMSH and [161Tb]Tb-crown-αMSH.